Pharmaceutical thrombosis prevention in XXXX .

@entity556 @entity1423 @entity326 @entity1031 @entity74 @entity857 @entity65
@entity65 are a leading cause of morbidity and mortality in modern society. As a result of this, great efforts have been made to establish regimens for prophylaxis and treatment of such disorders. Pharmacological intervention is also a prerequisite for the success of other therapeutic approaches, e.g. coronary angioplasty. Prevention of @entity1423 is a goal that can be achieved by counteracting various receptors on the platelet surface. The main attentions for such interventions are focused on inhibiting the glycoprotein IIb/IIIa receptor. So far, they are limited to intravenous usage. @entity857 receptor inhibitors are available for intravenous and oral usage. Their effect is, at least partly, also exerted via the counteraction of @entity857 -mediated activation of the glycoprotein IIb/IIIa complex. An oral direct @entity556 inhibitor is under clinical evaluation. This review focuses on @entity74 , but recent advances within new fields of anticoagulation (i.e., treatment of severe @entity326 and a novel approach to prevent @entity1031 during surgery) should not be overlooked.
